REGENXBIO, Inc. Stock News

ROCKVILLE, Md. , Jan. 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced data from its RGX-121 (clemidsogene lanparvovec) program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will be shared at the 21st Annual WORLDSymposium™ 2025, taking place in San Diego, CA February 3-7, 2025.

Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025. Partnership established with Nippon Shinyaku to develop RGX-121 and RGX-111 for the treatment of patients with MPS II and MPS I respectively. Data from both the ASCENT and ATMOSPHERE pivotal studies, using ABBV-RGX-314 for the treatment of patients with Wet Age-Related Macu...

Regenxbio Inc. remains undervalued despite its cutting-edge AAV gene therapy technology and promising assets like RGX-314 for wet AMD and RGX-121 for MPS II. RGX-314, partnered with AbbVie, targets wet AMD with global regulatory submissions expected in H1 2026; RGX-121 has a rolling BLA submission expected to complete in Q1 2025. Financially, RGNX has a market cap of $344mn and a cash balance o...

REGENXBIO to receive $110 million upfront, potential milestone payments of up to $700 million and meaningful double-digit royalties on net sales, and lead manufacturing Nippon Shinyaku to lead commercialization of first potential gene therapies for Mucopolysaccharidosis II (MPS II) and Mucopolysaccharidosis I (MPS I) in U.S. and Asia REGENXBIO retains rights to RGX-121 Priority Review Voucher (...

Pivotal data evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet age-related macular degeneration (wet AMD) are expected in 2026 AbbVie and REGENXBIO will plan the Phase 3 clinical program of investigational ABBV-RGX-314 in diabetic retinopathy (DR) NORTH CHICAGO, Ill. and ROCKVILLE, Md.

NEW YORK , Dec. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range.

Alignment achieved with FDA on AFFINITY DUCHENNE® pivotal program and access to accelerated approval; BLA expected in 2026 Pivotal trial of RGX-202 is enrolling ambulatory patients aged 1 and above with first patient dosed Phase I/II data show RGX-202 recipients exceeding external natural history and established benchmarks for clinical outcomes Functional improvements seen in all patients  trea...

-       Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE® trial and Michael Kelly, PhD, Chief Scientific Officer of CureDuchenne ROCKVILLE, Md.